Diabetes

Diagnoses of diabetes increased the most in South Dakota between 2018 and 2021 at 18.45%; diagnoses decreased the most in Hawaii at 15.61%. More, here.

Higher time in optimal glycemic range was associated with reduced risk for preeclampsia and for birth weight larger than gestational age, new research found.

The statistically significant improvements in MASH with survodutide were seen without worsening fibrosis and included a relative reduction of steatosis of 30%.

Your daily dose of the clinical news you may have missed.

Findings from new study suggest that promoting healthy coping strategies for stress during early life can reduce cardiometabolic risk, report researchers.

Your daily dose of the clinical news you may have missed.

AHA 2023: Semaglutide 2.4 mg reduced the risk of serious cardiovascular events by 20% in patients with obesity and overweight with established CVD but without diabetes, according to full SELECT trialresults.

Experts highlight considerations for patients with chronic kidney disease and other comorbid conditions, particularly diabetes, in terms of screening and preventative care.

Experts discuss key challenges in testing and diagnosing a patient with chronic kidney disease, especially for those who are asymptomatic. In addition, they highlight new screening approaches to accurately identify these patients.

Your daily dose of the clinical news you may have missed.

A novel study strongly suggests that pre-pregnancy obesity rather than associated adverse pregnancy outcomes is the "culprit" in postpartum heart disease.

Robert Busch, MD, discusses common screening methods to detect chronic kidney disease (CKD) and how he utilizes the Kidney Disease: Improving Global Outcomes (KDIGO) guidelines in his practice.

Dhiren Patel, PharmD, and Robert Busch, MD, present an overview of chronic kidney disease (CKD) and how it may impact a patient.

The phase 3 semaglutide kidney outcomes trial will be stopped immediately with FLOW read out expected in early 2024, the company said.

The first 10 drugs identified for negotiations under the Inflation Reduction Act include several well advertised agents indicated to treat diabetes, heart failure, and other chronic diseases.

The newly named centers across the country will work closely with communities to focus research on populations at greatest risk for perinatal morbidity and mortality.

Patients with diabetes will be able to save money when ordering insulin and commonly prescribed products, such as continuous glucose monitors and pumps.

Excess CVD mortality among Black vs White adults was diminished after control for behavior/metabolic factors and negligible after adjustments for SDOH, a new study reveals.

A daily dose of clinical news on Patient Care you may have missed.

A daily dose of clinical news on Patient Care you may have missed.

The new policy is helping people who are taking insulin save money and helping others to afford it in the first place, says a study coauthor from the USC Sol Price School of Public Policy .

Reductions in LDL-C, HbA1c, and body weight were associated with a variety of vegetarian diets in participants with or at high risk for cardiovascular disease.

Since 2014, the age-adjusted mortality rate for diabetes and CVD has increased by 1% after an overall decline between 1999 and 2019, new research finds.

The expanded indication widens the patient population eligible for the novel siRNA therapy to include high-risk patients on maximum statin Rx who have not had a CV event.

In a study of over 26 000 participants, statin use was associated with reduced risk for all-cause and CV mortality compared to placebo.

The ADA's annual update includes refined criteria for type 1 diabetes screening and detailed guidance on detection and management of NAFLD and NASH.

KidneyIntelX.dkd, a first-in-class AI-enabled prognostic test, stratifies risk of DKD progression in 5 years and is specific for early stage disease.

Eden Miller, DO, shares key takeaways on how personalized treatment helps in the management of diabetes.

Elizabeth Holt, MD, FACE, and Eden Miller, DO, comment on the pros and cons of real-world data studies, looking particularly at the study of the OneTouch Verio Flex meter and the OneTouch Reveal apps.

Experts discuss steps to introduce the OneTouch Verio Flex meter and the OneTouch Reveal app to patients to better manage diabetes.